RT Journal Article SR Electronic T1 Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 1112 OP 1117 DO 10.1136/ijgc-00009577-200411000-00008 VO 14 IS 6 A1 P. PAUTIER A1 A. REY A1 C. HAIE-MEDER A1 P. KERBRAT A1 J. L. DUTEL A1 P. GESTA A1 F. BRYARD A1 P. MORICE A1 P. DUVILLARD A1 C. LHOMMÉ YR 2004 UL http://ijgc.bmj.com/content/14/6/1112.abstract AB Uterine sarcoma is a poor prognosis disease, with a high risk of metastatic relapse. We conducted a study of adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy (n = 18). The results were then compared in a matched case-controlled study to radiotherapy alone (n = 16) or no therapy at all (n = 2). Chemotherapy consisted in three cycles of adriamyein-platinum-ifosfamide (API) (doxorubicin 60 mg /m2 on day 1; cisplatin 100 mg /m2 on day 2; ifosfamide 5 g /m2 on day 1 + mesna 5 g /m2 on day 1 + granulocyte colony-stimulating factor; q 3 weeks). Drug doses were reduced (20% for ifosfamide and cisplatin) four times (four patients) due to hematologic toxicity. Compared to a case-control study of adjuvant radiotherapy alone, results were not decreased by the addition of a toxic chemotherapy.Conclusion Adjuvant API chemotherapy followed by radiotherapy is a feasible protocol; a multicenter phase III study comparing radiotherapy alone versus API chemotherapy followed by radiotherapy just began in France.